Nonprofit · EIN 31-1611837
MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
Also known as LINDA TANTAWI
Tax-exempt · UNIONDALE, NY 11556
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| June 30, 2025 | 990 | $37,190,710 | $27,180,092 | $10,010,618 | $91,535,774 | $12,507,342 | $79,028,432 |
| June 30, 2024 | 990 | $22,749,028 | $30,962,554 | -$8,213,526 | $75,802,153 | $10,919,729 | $64,882,424 |
| June 30, 2023 | 990 | $18,297,575 | $28,681,699 | -$10,384,124 | $78,560,475 | $9,303,185 | $69,257,290 |
Financial details: 990 for the year ended June 30, 2025
Revenue
- Contributions, gifts and grants
- $34,677,585
- Program service revenue
- $0
- Investment income
- $2,436,168
- Royalties
- $76,957
- Net gain from sales of assets
- $233,280
- Other revenue
- $76,957
Expenses
- Grants and similar amounts paid
- $18,049,864
- Compensation of officers, directors and key employees
- $1,345,414
- Other salaries and wages
- $2,757,864
- Salaries, compensation and benefits (total)
- $4,909,781
- Professional fundraising fees
- $25,575
- Legal fees
- $3,102
- Occupancy
- $112,457
- Depreciation
- $38,727
- Program services (functional)
- $21,820,537
- Management and general (functional)
- $2,304,178
- Fundraising (functional)
- $3,055,377
Balance sheet and other
- Total assets, start of year
- $75,802,153
- Total assets, end of year
- $91,535,774
- Total liabilities, end of year
- $12,507,342
- Net assets, end of year
- $79,028,432
- Land, buildings and equipment
- $165,049
- Publicly traded securities
- $71,046,044
- Net assets without donor restrictions
- $66,740,484
- Net assets with donor restrictions
- $12,287,948
- Gross receipts
- $105,190,515
- Employees
- 26
- Volunteers
- 1,059
- Year formed
- 1998
- State of legal domicile
- NY
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended June 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| LINDA TANTAWI | CEO Officer | 40 | $489,273 | $39,510 |
| KERRI KAPLAN | PRESIDENT Officer | 40 | $341,967 | $40,938 |
| FAISAL JAWAID | CFO Officer | 40 | $287,237 | $41,045 |
| ANDREW RAKEMAN | VP RESEARCH Highest-paid employee | 40 | $272,473 | $41,720 |
| GLEN PECK | SVP TECHNOLOGY & BUSINESS INTELLIGENCE Highest-paid employee | 40 | $268,413 | $39,490 |
| JACLYN P LYMAN | HEAD CLINICAL RESEARCH & DEVELOPMENT Highest-paid employee | 40 | $258,870 | $21,280 |
| STEPHANIE DERGARABEDIAN | NATIONAL DIRECTOR OF DEVELOPMENT Highest-paid employee | 40 | $179,133 | $35,668 |
| SUSAN M JACOBSON | DIRECTOR EXTERNAL & COMMUNITY RELATIONS Highest-paid employee | 40 | $166,081 | $20,129 |
| ANDREW LUSTGARTEN | CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| ROBERT F VIZZA | CHAIRMAN EMERITUS Trustee or director, Officer | 2 | $0 | $0 |
| JENNIE FORTUNOFF | SECRETARY Trustee or director, Officer | 2 | $0 | $0 |
| PHILIP D'AMBROSIO | TREASURER Trustee or director, Officer | 2 | $0 | $0 |
| ADAM SILVER | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| SOMMER BAZURO PHD | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JOHN H COBB | DIRECTOR Trustee or director | 2 | $0 | $0 |
9 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| JESSICA LUSTGARTEN COURTEMANCHE | DIRECTOR Trustee or director | 2 | $0 |
| MARCIA LUSTGARTEN | DIRECTOR Trustee or director | 2 | $0 |
| SHEILA MAHONY | DIRECTOR Trustee or director | 2 | $0 |
| CHARLES R SCHUELER | DIRECTOR Trustee or director | 2 | $0 |
| WILLA SHALIT | DIRECTOR Trustee or director | 2 | $0 |
| SCOTT PENBERTHY | DIRECTOR Trustee or director | 2 | $0 |
| SELWYN VICKERS | DIRECTOR Trustee or director | 2 | $0 |
| AARON KANTOFF | DIRECTOR Trustee or director | 2 | $0 |
| RICHARD R BARAKAT MD MBA | DIRECTOR Trustee or director | 2 | $0 |
990 for the year ended June 30, 2024: 27 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| LINDA TANTAWI | CEO Officer | 40 | $465,053 | $55,921 |
| KERRI KAPLAN | PRESIDENT Officer | 40 | $328,848 | $49,145 |
| GLEN PECK | SVP TECHNOLOGY & BUSINESS INTELLIGENCE Highest-paid employee | 40 | $260,177 | $61,671 |
| ANDREW RAKEMAN | VP RESEARCH Highest-paid employee | 40 | $250,561 | $60,476 |
| FAISAL JAWAID | CFO Officer | 40 | $258,102 | $46,899 |
| STEPHANIE DERGARABEDIAN | NATIONAL DIRECTOR OF DEVELOPMENT Highest-paid employee | 40 | $156,431 | $47,745 |
| JACLYN P LYMAN | HEAD CLINICAL RESEARCH & DEVELOPMENT Highest-paid employee | 40 | $175,556 | $22,671 |
| SUSAN M JACOBSON | DIRECTOR EXTERNAL & COMMUNITY RELATIONS Highest-paid employee | 40 | $155,304 | $38,515 |
| ANDREW LUSTGARTEN | CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| CHARLES F DOLAN | CHAIRMAN EMERITUS (END 3/31/24) Trustee or director, Officer | 2 | $0 | $0 |
| ROBERT F VIZZA | CHAIRMAN EMERITUS Trustee or director, Officer | 2 | $0 | $0 |
| JENNIE FORTUNOFF | SECRETARY Trustee or director, Officer | 2 | $0 | $0 |
| PHILIP D'AMBROSIO | TREASURER Trustee or director, Officer | 2 | $0 | $0 |
| JAMES L DOLAN | VICE CHAIRMAN (END 3/31/24) Trustee or director, Officer | 2 | $0 | $0 |
| ADAM SILVER | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| SOMMER BAZURO PHD | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JOHN H COBB | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JESSICA LUSTGARTEN COURTEMANCHE | DIRECTOR Trustee or director | 2 | $0 | $0 |
| QUENTIN F DOLAN | TRUSTEE (END 3/31/24) Trustee or director | 2 | $0 | $0 |
| MARCIA LUSTGARTEN | DIRECTOR Trustee or director | 2 | $0 | $0 |
| SHEILA MAHONY | DIRECTOR Trustee or director | 2 | $0 | $0 |
| CHARLES R SCHUELER | DIRECTOR Trustee or director | 2 | $0 | $0 |
| WILLA SHALIT | DIRECTOR Trustee or director | 2 | $0 | $0 |
| SCOTT PENBERTHY | DIRECTOR Trustee or director | 2 | $0 | $0 |
| SELWYN VICKERS | DIRECTOR Trustee or director | 2 | $0 | $0 |
| AARON KANTOFF | DIRECTOR (AS OF 6/7/2024) Trustee or director | 2 | $0 | $0 |
| RICHARD R BARAKAT MD MBA | DIRECTOR (AS OF 6/7/2024) Trustee or director | 2 | $0 | $0 |
990 for the year ended June 30, 2023: 28 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| LINDA TANTAWI | CEO Officer | 40 | $430,564 | $29,537 |
| CATHERINE WEBER | VP DEV OPS & CONST SVCS (END 7/31/22) Former | 40 | $371,741 | $18,245 |
| KERRI KAPLAN | PRESIDENT Officer | 40 | $330,102 | $17,573 |
| GLEN PECK | SVP TECHNOLOGY & BUSINESS INTELLIGENCE Highest-paid employee | 40 | $262,312 | $25,975 |
| ANDREW RAKEMAN | VP RESEARCH Highest-paid employee | 40 | $248,673 | $25,376 |
| FAISAL JAWAID | CFO Officer | 40 | $197,906 | $2,480 |
| STEPHANIE DERGARABEDIAN | NATIONAL DIRECTOR OF DEVELOPMENT Highest-paid employee | 40 | $148,385 | $20,010 |
| SUSAN M JACOBSON | DIRECTOR EXTERNAL & COMMUNITY RELATIONS Highest-paid employee | 40 | $130,890 | $9,731 |
| PETER S CASALINO | DIRECTOR DATA SERVICES Highest-paid employee | 40 | $105,037 | $19,155 |
| ANDREW LUSTGARTEN | CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| JAMES L DOLAN | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| ADAM SILVER | VICE CHAIRMAN Trustee or director, Officer | 2 | $0 | $0 |
| JENNIE FORTUNOFF | SECRETARY Trustee or director, Officer | 2 | $0 | $0 |
| PHILIP D'AMBROSIO | TREASURER Trustee or director, Officer | 2 | $0 | $0 |
| WILLIAM BELL | TREASURER/DIRECTOR (END 10/27/22) Trustee or director, Officer | 2 | $0 | $0 |
| CHARLES F DOLAN | CHAIRMAN EMERITUS Trustee or director | 2 | $0 | $0 |
| ROBERT F VIZZA | CHAIRMAN EMERITUS Trustee or director | 2 | $0 | $0 |
| SOMMER BAZURO PHD | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JOHN H COBB | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JESSICA LUSTGARTEN COURTEMANCHE | DIRECTOR Trustee or director | 2 | $0 | $0 |
| QUENTIN F DOLAN | TRUSTEE Trustee or director | 2 | $0 | $0 |
| KENNETH GOODMAN MD FACR | DIRECTOR Trustee or director | 2 | $0 | $0 |
| MARCIA LUSTGARTEN | DIRECTOR Trustee or director | 2 | $0 | $0 |
| SHEILA MAHONY | DIRECTOR Trustee or director | 2 | $0 | $0 |
| CHARLES R SCHUELER | DIRECTOR Trustee or director | 2 | $0 | $0 |
| WILLA SHALIT | DIRECTOR Trustee or director | 2 | $0 | $0 |
| SELWYN M VICKERS | DIRECTOR (AS OF 6/15/2023) Trustee or director | 2 | $0 | $0 |
| SCOTT PENBERTHY | DIRECTOR (AS OF 6/15/2023) Trustee or director | 2 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 504 RXR PLZ, UNIONDALE, NY 11556-0500
- Principal officer (990 for 2024)
- LINDA TANTAWI, 504 RXR PLAZA, UNIONDALE, NY 11556
- Signed the 990
- LINDA TANTAWI, CEO
- Phone
- (516) 737-1550
- Website
- WWW.LUSTGARTEN.ORG
- Return prepared by
- KPMG LLP
Mission
THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE LUSTGARTEN FOUNDATION IS BOLDLY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FOCUSES ON TRANSLATING OUR UNDERSTANDING OF THE UNDERLYING BIOLOGY OF PANCREATIC CANCER INTO CLINICAL APPLICATIONS TO CHANGE, EXTEND, AND ULTIMATELY SAVE PATIENTS' LIVES. IN FY25, THE FOUNDATION AWARDED $18 MILLION TO FUEL CUTTING-EDGE PANCREATIC CANCER RESEARCH, INCLUDING 10 NEW GRANTS TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. RESEARCH EFFORTS ARE CONCENTRATED ON THREE KEY PILLARS: EARLY DETECTION AND INTERCEPTION, DRUG DEVELOPMENT, AND PERSONALIZED MEDICINE.
Program accomplishments
- RESEARCH PROGRAM: THE LUSTGARTEN FOUNDATION'S MISSION IS TO ADVANCE THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. 2025 MARKED THE FOUNDATION'S 27TH YEAR OF DRIVING PIONEERING PANCREATIC CANCER RESEARCH BREAKTHROUGHS, ACCELERATING PROGRESS FASTER THAN EVER BEFORE AND PROVIDING A MORE HOPEFUL FUTURE FOR ALL PATIENTS. SEE SCHEDULE O.Expenses $19,810,727 · grants $18,049,864
- PUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD, FUNDING PREEMINENT PANCREATIC CANCER RESEARCHERS, DRIVING THE PURSUIT OF BOLD AND INNOVATIVE SCIENCE TOWARD EARLIER DETECTION AND BETTER TREATMENTS, AND TRANSFORMING PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FUNDS RESEARCH WHERE CREATIVE RISKS YIELD HIGH REWARDS TO ACCELERATE AND EXPAND LIFE-SAVING TREATMENT OPTIONS. WE BELIEVE TIME IS EVERYTHING TO PATIENTS AND THEIR FAMILIES, AND THAT COMMUNITY IS POWER. LUSTGARTEN PROGRAMS AND EVENTS PROVIDE PEOPLE AFFECTED BY PANCREATIC CANCER A VOICE AND A PLACE TO CREATE HOPE, TOGETHER. SEE SCHEDULE O.Expenses $1,235,976
- PROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SCIENTIFIC LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH FUNDED SCIENTISTS AND DIRECTORS OF THE LABS PROGRAM SITES AND COLLABORATING ORGANIZATIONS. ADDITIONALLY, THE LUSTGARTEN FOUNDATION PROVIDED SUPPORT FOR THE AACR SPECIAL CONFERENCE IN PANCREAS CANCER RESEARCH, AACR-LUSTGARTEN FOUNDATION-MARK FOUNDATION JOINT WORKSHOP ON SOLVING THE EARLY STAGE DIAGNOSIS FOR RALCITRANT CANCERS, THE GORDON RESEARCH CONFERENCE ON PANCREATIC DISEASES, THE INTERNATIONAL WOMEN'S DAY SYMPOSIUM AT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, AND THE FOUNDATION'S SCIENTIFIC ADVISORY BOARD ANNUAL MEETING. SEE SCHEDULE O.Expenses $773,834
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in June, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | June 30, 2026 | November 16, 2026 | Not due yet |
| 2024 | June 30, 2025 | November 17, 2025 | 990 on file |
| 2023 | June 30, 2024 | November 15, 2024 | 990 on file |
IRS record
- EIN
- 31-1611837
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1999
- Accounting year ends
- June
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Human services (P112)
- Assets (IRS master file)
- $91,535,774
- Income (IRS master file)
- $105,190,515
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | June 2025 | $37,190,710 | $27,180,092 | $91,535,774 | XML |
| 990 | June 2024 | $22,749,028 | $30,962,554 | $75,802,153 | XML |
| 990 | June 2023 | $18,297,575 | $28,681,699 | $78,560,475 | XML |
| 990 | June 2022 | $30,446,505 | $33,834,657 | $78,505,397 | IRS |
| 990 | June 2021 | – | – | – | IRS |
| 990 | June 2020 | – | – | – | IRS |
| 990 | December 2017 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 31-1611837).
Questions about MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
- What is the EIN of MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION?
- The employer identification number (EIN) of MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION is 31-1611837.
- Is MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1999.
- Are donations to MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION due?
- The return for tax year 2025 (the year ending June 30, 2026) is due November 16, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended June 2025.
- Who is the principal officer of MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION?
- The 990 for the year ended June 30, 2025 names LINDA TANTAWI.
- Who are the officers and directors of MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION?
- The 990 for the year ended June 30, 2025 lists 24 people; 8 received compensation from the organization, the highest $489,273 (LINDA TANTAWI, CEO).
- How much revenue does MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION have?
- On its 990 for the year ended June 30, 2025 it reported revenue of $37,190,710, expenses of $27,180,092 and total assets of $91,535,774 at year end.
Other nonprofits in UNIONDALE
- HEELING SOLES INC EIN 47-2101467 · last filed 990-EZ for 2024
- ROYALE ROYALTIES INC EIN 87-3098999 · last filed 990-PF for 2025
- MILLENNIUM SISTAHS EIN 11-3523194 · last filed 990-N for 2025
- CENTRAL COUNCIL OF THE SOCIETY OF ST VINCENT DE PAUL IN THE DIOCESE EIN 30-0468238 · last filed 990-N for 2024
- SUBLIME HUMAN SERVICES INC EIN 92-2779805 · last filed 990-N for 2023
- POWER OF PRAYER RESTORATION MINISTRY INC EIN 99-1429504
- THE COMMUNITY CLOUT INC EIN 47-5649926 · last filed 990-N for 2025
- KNOWLEDGE IS KEY INC EIN 46-5499895 · last filed 990-N for 2024